Synergy Pharmaceuticals (SGYP) : Analyst Rating Update

Synergy Pharmaceuticals (SGYP) : 2 analysts are covering Synergy Pharmaceuticals (SGYP) and their average rating on the stock is 1, which is read as a Strong Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.

Synergy Pharmaceuticals (SGYP) stock is expected to deviate a maximum of $6.01 from the average target price of $10.75 for the short term period. 2 Street Experts have initiated coverage on the stock with the most promising target being $15 and the most muted being $7.

Synergy Pharmaceuticals (NASDAQ:SGYP): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $3.80 and $3.76 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $3.87. The buying momentum continued till the end and the stock did not give up its gains. It closed at $3.86, notching a gain of 1.05% for the day. The total traded volume was 1,919,618 . The stock had closed at $3.82 on the previous day.

Also, Brokerage firm Rodman & Renshaw maintains its rating on Synergy Pharmaceuticals (NASDAQ:SGYP). As per the latest information, the brokerage house lowers the price target to $15 per share from a prior target of $16. The shares have been rated Buy. The rating by the firm was issued on May 9, 2016. The company shares have dropped -57.65% from its 1 Year high price. On Jul 30, 2015, the shares registered one year high at $10.15 and the one year low was seen on Mar 23, 2016. The 50-Day Moving Average price is $3.66 and the 200 Day Moving Average price is recorded at $3.64.

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Companys platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Companys products include plecanatide, SP-333 and FV-100. The Companys lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Companys subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *